Jesek J K, Martin N B, Broeder C E, Thomas E L, Wambsgans K C, Hofman Z, Ivy J L, Wilmore J H
Department of Kinesiology and Health Education, University of Texas, Austin 78712.
Am J Cardiol. 1990 Dec 1;66(19):1336-41. doi: 10.1016/0002-9149(90)91164-2.
The extent to which lipolysis is attenuated during prolonged submaximal exercise during beta blockade was determined in 12 normotensive endurance-trained and 12 hypertensive sedentary men using nonselective drugs with and without intrinsic sympathomimetic activity (ISA). Initially, subjects performed a graded treadmill test to determine maximal oxygen uptake (VO2max). This was followed by 2-hour walks at 25 and 45% of the subject's VO2max under each of 3 treatments: pindolol (ISA), propranolol (non-ISA) and placebo. The distribution of medication was randomized and double blinded. Blood samples taken at rest and every 30 minutes during the 2-hour walks were analyzed to determine the concentrations of free fatty acids (FFA) and glycerol. On the basis of the respective changes in FFA, glycerols and the respiratory exchange ratio, beta-adrenergic blockade did not attenuate lipolysis in the untrained hypertensive subjects when compared with the placebo administration. However, beta blockade did demonstrate a tendency to attenuate lipolysis in the trained, normotensive subjects when compared with results after placebo administration. This was particularly evident at 30 minutes of exercise, when both glycerol and FFA concentrations were not increased above resting values under both conditions of beta blockade. No differences between pindolol and propranolol were observed. Therefore, a beta-blocking agent with ISA properties appears to have no clear benefit with respect to lipid metabolism during low and moderate intensity exercise. Furthermore, these data demonstrate that beta blockade does not inhibit exercise-induced lipolysis at low and moderate intensities of exercise as formerly believed, and is unlikely to be the cause of fatigue normally observed during work in patient populations taking beta-blocking medication.
在12名血压正常且接受过耐力训练的男性和12名久坐不动的高血压男性中,使用具有和不具有内在拟交感神经活性(ISA)的非选择性药物,确定了在β受体阻滞剂作用下长时间次最大运动期间脂肪分解减弱的程度。最初,受试者进行分级跑步机测试以确定最大摄氧量(VO2max)。随后,在三种治疗方式(吲哚洛尔(ISA)、普萘洛尔(无ISA)和安慰剂)下,受试者以其VO2max的25%和45%进行2小时的步行。药物分配是随机且双盲的。在休息时以及2小时步行期间每30分钟采集血样,分析游离脂肪酸(FFA)和甘油的浓度。根据FFA、甘油各自的变化以及呼吸交换率,与给予安慰剂相比,β肾上腺素能阻滞剂在未训练的高血压受试者中并未减弱脂肪分解。然而,与给予安慰剂后的结果相比,β受体阻滞剂在经过训练的血压正常受试者中确实显示出减弱脂肪分解的趋势。这在运动30分钟时尤为明显,此时在两种β受体阻滞剂作用条件下,甘油和FFA浓度均未升高至高于静息值。未观察到吲哚洛尔和普萘洛尔之间存在差异。因此,具有ISA特性的β受体阻滞剂在低强度和中等强度运动期间对脂质代谢似乎没有明显益处。此外,这些数据表明,β受体阻滞剂在低强度和中等强度运动中并不会像以前认为的那样抑制运动诱导的脂肪分解,并且不太可能是服用β受体阻滞剂药物的患者群体在工作期间通常观察到的疲劳的原因。